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Abstract
A 67-year-old woman with debilitation and massive ascites was admitted to our hospital
and diagnosed with stage IV scirrhous gastric cancer with peritoneal dissemination. After suc-
cessful nasojejunal tube feeding because of oral intake disability, TS-1 combined with paclitaxel
chemotherapy was selected. TS-1 at 80mg/m2 was given daily via nasojejunal tube for 2 weeks,
followed by a 1-week rest, and paclitaxel at 50mg/m2 was administered intravenously on day 1
and 8. There were no serious side effects. After 4 cycles, a partial response was observed and
percutaneous transesophageal gastro-tubing (PTEG) was placed. After the fifth cycle, she was
transferred to her home and received chemotherapy in an outpatient clinic. After 7 cycles, the
disease progressed, and TS-1 combined with low-dose cisplatin was administered for 3 cycles.
However, the patient died 16 weeks after discharge. PTEG was useful not only for a route of TS-1
administration, but also for receiving chemotherapy at home to maintain her quality.
KEYWORDS: TS-1 combined chemotherapy, gastric cancer, nasojejunal tube, percutaneous trans-
esophageal gastro-tubing
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A 67-year-old woman with debilitation and massive ascites was admitted to our hospital and diagnosed 
with stage IV scirrhous gastric cancer with peritoneal dissemination.  After successful nasojejunal tube 
feeding because of oral intake disability,  TS-1 combined with paclitaxel chemotherapy was selected.  
TS-1 at 80mg/m2 was given daily via nasojejunal tube for 2 weeks,  followed by a 1-week rest,  and 
paclitaxel at 50mg/m2 was administered intravenously on day 1 and 8.  There were no serious side 
eﬀects.  After 4 cycles,  a partial response was observed and percutaneous transesophageal gastro-
tubing (PTEG) was placed.  After the ﬁfth cycle,  she was transferred to her home and received che-
motherapy in an outpatient clinic.  After 7 cycles,  the disease progressed,  and TS-1 combined with 
low-dose cisplatin was administered for 3 cycles.  However,  the patient died 16 weeks after discharge.  
PTEG was useful not only for a route of TS-1 administration,  but also for receiving chemotherapy at 
home to maintain her quality.
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astric failure is common in gastric cancer 
patients,  who often become malnourished.  Place-
ment of feeding tubes into the stomach or small 
intestine can overcome some of the most common 
causes of impaired caloric intake caused by cancer 
[1].  The percutaneous transesophageal gastro-tubing 
technique (PTEG) was developed to drain gastroin-
testinal contents in patients with malignant obstruc-
tion or as an access route for enteral feeding [2,  3].  
PTEG is a safe,  eﬀective and simple method that 
enabled patients to continue receiving further medical 
care at home [2].
　 We report a patient with inoperable gastric cancer 
who underwent combination chemotherapy with TS-1 
administration using a nasojejunal feeding tube,  resul-
ting in tumor regression,  and who was subsequently 
treated in an outpatient clinic using PTEG,  to main-
tain her quality of life.
Case Report
　 A stomach abnormality had been pointed out on a 
gastric radiograph of a 67-year-old woman 5 years 
previously,  but she had refused further examinations 
at that time.  Recently,  a 4-kg body-weight loss over 
one month,  incontinence,  diarrhea and edema of the 
lower extremities caused her to visit a medical practi-
tioner,  on the gastric radiograph,  gastric cancer was 
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highly suspected,  but she refused further examination 
or therapy again and received only palliative therapy 
at home.  However,  her general conditions gradually 
declined,  and she became dependent for all activities 
of daily living.  She was then referred to Kojima 
Municipal Hospital.  She became bedridden,  and physi-
cal examination showed that the abdomen was dis-
tended with massive ascites.  Abdominal computed 
tomography (CT) showed a thick stomach wall and 
paraaortic lymph node adenopathy with a large amount 
of ascitic ﬂuid.  Gastroendoscopy showed a type 4 
inﬁltrating lesion in almost the whole stomach,  and a 
biopsy specimen revealed poorly diﬀerentiated adeno-
carcinoma or signet ring cell carcinoma.  The clinical 
stage was T3N3H0P1CY1M0 stage IV according to 
the Japanese Classiﬁcation of Gastric Cancer (Second 
English version).
　 A nasojejunal tube was placed for enteral nutrition 
with a formula (Ensure Liquid (Abbott Japan Co.,  
Ltd.,  Tokyo,  Japan)) because of oral intake inability 
with impaired gastric motility.  On day 11 after admis-
sion,  renal function worsened because of external 
compression of the ureter therefore,  a ureteral stent 
was inserted.  On day 19,  a CT scan before chemo-
therapy showed increased ascites and rectal stenosis 
by external invasion,  and a decompression tube was 
inserted transanally into the sigmoid colon (Fig.  1).  
Once enteral nutrition was successful,  the patient 
changed her attitude and became eager to live and had 
a positive attitude to chemotherapy.  On day 23,  TS-1
＋paclitaxel was administered.  TS-1 was adminis-
tered twice a day,  at a dose of 100mg/body/day 
(80mg/m2/day),  for 14 consecutive days via a nasoje-
junal tube followed by a 7-day rest period.  TS-1 was 
administered by a simple suspension method in which 
capsules were dissolved in hot water without crushing.  
Paclitaxel was administered intravenously at a dose of 
60mg/body (50mg/m2) on days 1 and 8.  Two cycles 
were completed,  and the transanal tube was naturally 
expelled because of improving colonic stricture.  After 
3 cycles,  the urinary stent was removed due to uri-
nary infection,  but ureteral stenosis did not occur.  
After 4 cycles were completed,  a CT showed com-
plete remission of paraaortic lymph nodes and 
decreased ascites (Fig.  2).  Her activity was gradually 
restored and she could walk with help.  She was eager 
to go home and percutaneous transesophageal gastro-
tubing was placed on day 108.  After the ﬁfth cycle on 
day 128,  she was transferred to home care.  After the 
seventh cycle,  6 weeks after discharge,  TS-1 and 
paclitaxel failed because malignant pleural eﬀusion 
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Fig. 2　 Abdominal CT scan (after four cycles of chemotherapy) 
Complete remission of paraaortic lymph node metastasis and 
decreased ascites.
A B
Fig. 1　 Abdominal CT scan (before chemotherapy).  A, Thickness of the stomach wall (arrowhead),  paraaortic lymph node adenopathy 
(arrow); B,  An large amount of ascites and rectal stricture (arrow).
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was observed.  TS-1 was then combined with weekly 
low-dose cisplatin.  TS-1 was administered at 100mg/
body/day (80mg/m2/day) for 2 weeks,  followed by a 
1-week rest.  Cisplatin was administered at 25mg/
body (20mg/m2) on day 1 and 8.  After 3 cycles,  16 
weeks after discharge,  she was admitted to our hospi-
tal because of pulmonary failure with eﬀusion and died 
the next day.  During home care,  there were no seri-
ous side eﬀects or technical problems.
Discussion
　 Poorly diﬀerentiated gastric carcinoma has a poor 
prognosis [4],  especially the scirrhous type,  despite 
suﬃcient chemotherapy,  with a median survival of 6 
months [5].  Metastatic gastric cancer is considered 
incurable and has a poor prognosis [6],  most patients 
with peritoneal dissemination die within 6 months of 
diagnosis [7,  8].  In such a situation,  optimal pallia-
tion and prolongation of life are the main goals of 
treatment.
　 TS-1 has been proved to be eﬀective for gastric 
cancer patients with an overall response rate of 
40-49ｵ in a phase II study [9,  10].  In patients with 
peritoneal dissemination,  TS-1 was also eﬀective with 
acceptable toxicity and improvement of prognosis [7,  
8].  After the oral administration of S-1,  5-ﬂuorou-
racil passes through the peritoneum,  and a high con-
centration is maintained in the peritoneal cavity [11].
　 Paclitaxel is also considered an active chemothera-
peutic agent for gastric cancer and in a retrospective 
study of a weekly regimen as a second line,  the overall 
response was 16-24ｵ with a median survival of 5-7.8 
months [12,  13].  In a pharmacokinetic study,  pacli-
taxel was highly inﬁltrative into ascites [14];  
Wiernik PH et al.  reported that the concentration of 
paclitaxel in ascitic ﬂuid increased for several hours 
and then stabilized at a level approximately 40ｵ 
above that in plasma [15].  Based on these results,  a 
combination of TS-1 and paclitaxel was expected to be 
eﬀective in gastric cancer,  especially in peritoneal 
dissemination.  Previous phase I/II trials [16-18] of 
TS-1 combined with paclitaxel showed that the overall 
response rate was about 50ｵ.  In terms of adverse 
events,  grade 3 or more hematological and non-hema-
tological toxicities occurred in less than 20ｵ and 
28ｵ of cases,  respectively [18].  On the other hand,  
TS-1 combined with cisplatin is also considered to be 
eﬀective chemotherapy for gastric cancer.  A phase I/
II study in patients with advanced gastric cancer 
obtained a response of 76ｵ,  with a median overall 
survival of 383 days and tolerable toxicity [19].  
However,  this regimen requires a short hospital stay 
for hydration to prevent the renal toxicity induced by 
cisplatin.  In our patient with renal function problems 
and general edema with massive ascites,  such a regi-
men was likely to induce further impairment of renal 
function and general edema.  In addition,  the patient 
did not wish to undergo this treatment because of 
required the hospital stay.  On the basis of these 
details,  platinum-based chemotherapy was contraindi-
cated.  Furthermore,  the patientʼs poor general condi-
tion necessitated chemotherapy with low toxicity and 
high eﬃcacy,  and TS-1 and paclitaxel combination 
chemotherapy was thus considered the best option.
　 For patients with oral intake disability,  TS-1 
administration through gastrostomy [20] or a feeding 
tube [7,  21] is an alternative method and useful 
option that improves the quality of life and enables 
home care.  A pharmacokinetics study revealed that 
plasma concentration levels via a catheter were equiva-
lent to oral intake,  and no severe adverse eﬀects,  
particularly on the digestive systems,  were observed 
[20,  21].  In patients with peritoneal metastasis and 
ascites without bowel obstruction or with oral intake 
disability due to gastric dysfunction alone,  an appro-
priate access route is required for enteral nutrition or 
drug intake; available options include surgical or 
endoscopic jejunostomy.  A surgical approach is likely 
not to be well tolerated in already compromised 
patients,  and an endoscopic approach might be chal-
lenging.  On the other hand,  long-term use of a nasoje-
junal tube feeding should be avoided,  especially in an 
outpatient setting,  because it would likely increase the 
incidence of complications,  including rhinitis,  aspira-
tion pneumonia,  and technical problems such as inad-
vertent removal or occlusion,  as well as cosmetic 
issues and discomfort.  By contrast,  PTEG was useful 
and enabled the possibility of transfer to home care 
and was eﬀectively improved her quality of life.  
Further,  if enteral feeding using this methods should 
have failed because of intestinal obstruction due to 
carcinomatosa with resistance to chemotherapy,  other 
options,  such as decompression at the site would have 
been available.  In our case,  fortunately,  there were 
no technical or serious problems for management of 
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PTEG at home.  In such a deteriorated case,  home 
care is usually considered diﬃcult to manage; however,  
with the support of her husband,  the patient was able 
to live at home.  The conjugal bonds were renewed and 
the pateintʼs last days were precious and memorable,  
making her death less painful.
　 In conclusion,  TS-1 administration via a nasojeju-
nal feeding tube was an eﬀective administration 
method that enabled a more eﬀective combination 
chemotherapy regimen.  PTEG was less stressful and 
an appropriate choice for administering chemotherapy 
at home,  and maintaining the dying patientʼs quality of 
life.
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